- Genetically modified cell lines best reflect MOA (Mechanism of Action)
- Higher activity and larger assay window for robust and reproducible cell-based bioassay
- Comprehensive application data to support assay development and validation
- Full tracible record, stringent quality control and validated cell passage stability
- Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
- Global commercial license assistance whenever regulatory filing is required
描述(Description)
The CHO/Human CD16a (158V) Stable Cell Line was engineered to express full length human CD16a receptor mutated to a Valine (V) at amino acid 158 with different levels of CD16a (158V) expression (High, Medium, Low), which can be used to test agonist antibody whether in a CD16a (158V)-dependent manner to strengthen the agonistic activity. When co-cultured with Human 4-1BB Reporter Cell and anti-4-1BB agonist antibody, the anti-4-1BB antibody can be crosslinked, thereby strengthening 4-1BB pathway-activated luminescence.
应用说明(Application)
• Useful for cell-based CD16a (158V) binding assay
• Useful for CD16a (158V)-mediated crosslinking
生长特性(Growth Properties)
Adherent
筛选标记(Selection Marker)
Hygromycin (20 μg/mL)
培养基(Culture Medium)
F-12K+ 10% FBS
冻存液(Freeze Medium)
Serum-free cell cryopreservation medium
装量(Quantity)
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
存储(Storage)
Frozen in liquid nitrogen.
支原体检测(Mycoplasma Testing)
Negative
无菌检测(Sterility Testing)
Negative
使用说明(Instructions for Use)
See data sheet for detailed culturing and assay protocol.
Receptor Assay
Expression analysis of human CD16a on CHO/Human CD16a (158V) Stable Cell Line by FACS.
Cell surface staining using PE-labeled anti-human CD16a antibody was performed on CHO/Human CD16a (158V) Stable Cell Line with different expression levels: CHO/Human CD16a (158V) Stable Cell Line (Low Expression); CHO/Human CD16a (158V) Stable Cell Line (Medium Expression); CHO/Human CD16a (158V) Stable Cell Line (High Expression).
Protocol
如有相关细胞池需求请联系我们
背景(Background)
CD16 is a low affinity Fc receptor, and has been identified as Fc receptors FcγRIIIa (CD16a) and FcγRIIIb (CD16b). These receptors bind to the Fc portion of IgG antibodies. CD16 encoded by two different highly homologous genes in a cell type-specific manner.CD16 is found on the surface of natural killer cells, neutrophil polymorphonuclear leukocytes, monocytes and macrophages. CD16a antigen is also known as Low affinity immunoglobulin gamma Fc region receptor III-A, Fc-gamma RIII-alpha. CD16b is a low-affinity, GPI-linked receptor expressed by neutrophils and eosinophils, whereas CD16a is an intermediate affinity polypeptide-anchored transmembrane glycoprotein expressed natural killer cells, macrophages, subpopulation of T-cells, immature thymocytes and placentaltrophoblasts.CD16a is involved in phagocytosis, secretion of enzymes and inflammatory mediators, antibodydependent cytotoxicity and clearance of immune complexes. Aberrant expression or mutations of CD16a is implicated in susceptibility to recurrent viral infections, systemic lupus erythematosus, and alloimmune neonatal neutropenia.
Limited Use&License Disclosure
- This cell line is provided for research use only. It is neither intended for any animal or human therapeutic use nor for any direct human in vivo use. You are restricted to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
- ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
- ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
- Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order.cn@acrobiosystems.com for further details.